The Biostatistics and Computational Biology Core will join and expand the existing Biostatistics Core and computational aspects of the existing Genomics Core of the current DF/HCC Prostate Cancer SPORE in one Core under the leadership of the Core Director, Dr. Meredith Regan, and Co-Director, Dr. Pablo Tamayo. The new integrated Biostatistics and Computational Biology Core reflects the growth of computational, data- intensive approaches to cancer research at cancer centers around the country. The Core personnel will draw from expertise at the Dana-Farber Cancer Institute (DFCI), the Harvard School of Public Health (HSPH), and the Broad Institute, a research collaboration of the Massachusetts Institute of Technology (MIT) and Harvard academic and medical communities that focuses on genomic medicine. The DF/HCC Prostate Cancer SPORE Biostatistics and Computational Biology Core will provide consultation and collaboration on all research activities within the SPORE, including Projects, Developmental Projects, Projects of the Career Development Awardees, and the other SPORE Cores to ensure the highest standards of scientific rigor in all areas, including study design, data management and integrity, and data analysis and interpretation.
The specific aims are to: 1. Provide biostatistical and computational biology expertise for the planning and design, conduct, analysis, and reporting of laboratory, genomic, animal, translational, clinical (including associated correlative studies), and epidemiological studies for SPORE projects, Developmental Projects, Projects of the Career Development Awardees, and other SPORE Cores. 2. Provide consultation on data collection, storage and quality assurance, statistics, and computational biology software and programs and coordination of laboratory results with parameters and outcomes from clinical studies or clinical/translational research databases. 3. Provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-09
Application #
8094500
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$415,679
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Pakula, Hubert; Linn, Douglas E; Schmidt, Daniel R et al. (2018) Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Methods Mol Biol 1786:131-151
Elfandy, Habiba; Armenia, Joshua; Pederzoli, Filippo et al. (2018) Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res :
Han, W; Gao, S; Barrett, D et al. (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710-721
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104
Pettersson, Andreas; Gerke, Travis; Penney, Kathryn L et al. (2018) MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:201-207
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362

Showing the most recent 10 out of 261 publications